Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMA COMPOUND vs COLYTE-FLAVORED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carisoprodol is a centrally acting muscle relaxant that acts through its metabolite meprobamate, which modulates GABA-A receptors and inhibits neuronal activity in the reticular formation and spinal cord. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.
Colyte is an osmotic laxative that induces diarrhea by retaining water in the colon through non-absorbable polyethylene glycol (PEG) and electrolytes, resulting in bowel cleansing.
Relief of discomfort associated with acute, painful musculoskeletal conditions,Off-label: management of muscle spasms, tension headaches
Colonoscopy preparation,Bowel cleansing prior to colorectal surgery,Bowel preparation for barium enema
1-2 tablets (carisoprodol 200mg/aspirin 325mg) orally 4 times daily.
4 liters orally as a single dose or in divided doses for colonoscopy preparation, or 1 liter orally every 10-15 minutes until 4 liters are consumed.
Carisoprodol: approximately 2-4 hours in adults with normal renal function. Meprobamate: approximately 10-12 hours. The prolonged half-life of meprobamate contributes to accumulation with repeated dosing, especially in elderly or renally impaired patients, leading to increased risk of sedation and dependence.
Not applicable; the drug acts locally in the gastrointestinal tract without significant systemic absorption. For the small fraction absorbed, a terminal elimination half-life of approximately 0.5-1 hour is estimated, but clinical relevance is negligible.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite); aspirin is hydrolyzed to salicylic acid via esterases in the liver and plasma.
Polyethylene glycol (PEG) is not significantly metabolized; it is excreted unchanged in feces.
Carisoprodol and its active metabolite meprobamate are primarily excreted renally. Approximately 60% of a dose is eliminated as unchanged carisoprodol and meprobamate in urine, with the remainder as various hydroxylated metabolites. Less than 1% is eliminated in feces. Meprobamate undergoes hepatic metabolism, and about 10-20% is excreted unchanged in urine.
Primarily eliminated in feces (≥95%) as intact drug via the gastrointestinal tract. Minimal systemic absorption; renal excretion accounts for <1% of the administered dose.
Carisoprodol: approximately 60% bound to plasma proteins, primarily albumin. Meprobamate: approximately 15-25% bound to plasma proteins.
Negligible (<5%) due to minimal systemic absorption; no specific binding proteins identified.
Carisoprodol: Vd approximately 0.5-1.0 L/kg, indicating distribution into total body water and some tissue binding. Meprobamate: Vd about 0.7 L/kg.
Not meaningful due to negligible systemic absorption. The small fraction absorbed distributes primarily in extracellular fluid; a theoretical Vd would be low (<0.2 L/kg), but not clinically relevant.
Oral: Carisoprodol is well absorbed with bioavailability >90%. The absorption rate may be slightly reduced with food, but extent is not significantly affected.
Oral bioavailability is <1% due to minimal gastrointestinal absorption; the drug acts locally within the intestinal lumen.
Cr Cl <30 m L/min: avoid use due to aspirin component; Cr Cl 30-50 m L/min: reduce dose or extend interval; monitor for carisoprodol accumulation.
Use with caution in patients with GFR <30 m L/min/1.73 m2; consider alternative bowel preparation. No specific dose adjustment defined.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to risk of fluid and electrolyte disturbances.
Not recommended for children under 12 years; safety and efficacy not established.
Not recommended for use in children; safety and efficacy not established.
Initiate at lowest dose (1 tablet); avoid use in patients with Cr Cl <30 m L/min; monitor for CNS depression and bleeding risk.
Use with caution; monitor for fluid and electrolyte imbalances, renal function, and volume status. Consider lower dose or split-dose regimen.
No FDA black box warning.
There is no FDA black box warning for Colyte.
Dependence and withdrawal: Carisoprodol can cause dependence, abuse, and withdrawal symptoms after prolonged use,Sedation: May impair mental or physical abilities; caution with driving or operating machinery,Bleeding risk: Aspirin component increases risk of bleeding, especially with alcohol, anticoagulants, or existing bleeding disorders,Hypersensitivity: Allergic reactions including anaphylaxis can occur
Risk of aspiration and esophageal perforation in patients with impaired gag reflex or altered consciousness,Electrolyte disturbances (e.g., hypernatremia, hypokalemia) in patients with renal impairment or dehydration,Cardiac arrhythmias in patients with electrolyte imbalances or QT prolongation,Colonic mucosal erosions or ulcerations with repeated use,Not for use in patients with gastrointestinal obstruction, perforation, or ileus
History of acute intermittent porphyria,Hypersensitivity to carisoprodol, meprobamate, aspirin, or any component,Severe hepatic or renal impairment,Gastrointestinal bleeding or peptic ulcer disease (active),Children with viral infections (Reye's syndrome risk),Third trimester of pregnancy (aspirin component)
Gastrointestinal obstruction,Gastric retention,Bowel perforation,Toxic colitis,Toxic megacolon,History of severe electrolyte abnormalities,Known hypersensitivity to any component
Avoid alcohol. Aspirin may cause gastrointestinal irritation; take with food or a full glass of water to reduce risk. Avoid high-dose vitamin C or acidic foods that may increase aspirin absorption and toxicity.
Only clear liquids are allowed during bowel preparation. Avoid milk, cream, soups with solid ingredients, red or purple liquids, and alcohol. Solid food should be avoided at least 2 hours before starting the solution. No food interactions with the drug itself; dietary restrictions are for the procedure.
Carisoprodol (Soma) is FDA Pregnancy Category C. Inadequate human data; animal studies suggest risk. Not recommended in first trimester due to potential teratogenicity. Aspirin component (if present in compound) is associated with increased risk of neural tube defects and fetal hemorrhage if used in third trimester. Avoid use during pregnancy unless benefit outweighs risk.
Category C: Not associated with major malformations; limited data in pregnancy. No known teratogenicity; use only if clearly needed.
Carisoprodol and its active metabolite meprobamate are excreted in breast milk. M/P ratio not well established. Concentrations may reach clinical significance. Potential for infant sedation, hypotonia, or withdrawal. Avoid breastfeeding while on this medication.
Excretion unknown; likely minimal systemic absorption. No M/P ratio available. Use with caution.
No established dosing adjustments for pregnancy. Due to increased renal clearance during pregnancy, consider that standard doses may be less effective. However, lack of safety data generally contraindicates use. If absolutely necessary, use lowest effective dose for shortest duration.
No dosage adjustment required; monitor for hypovolemia due to increased plasma volume.
Soma Compound contains carisoprodol (a centrally acting muscle relaxant) and aspirin (an NSAID). Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with a history of substance abuse, porphyria, or G6PD deficiency. Monitor for signs of CNS depression, especially when combined with alcohol or other sedatives. Aspirin increases bleeding risk; avoid in patients with bleeding disorders or those on anticoagulants. Do not use in children or adolescents with viral infections due to risk of Reye's syndrome.
Colyte-Flavored (PEG-3350 and electrolytes) is a colonic lavage solution used for bowel preparation prior to colonoscopy. Ensure adequate hydration: patients must consume all 4 liters (or split-dose regimen). Concurrent use of other laxatives or enemas is generally not needed. In patients with impaired gag reflex, renal insufficiency, or electrolyte abnormalities, use with caution. Monitor for bloating, nausea, and aspiration risk. Avoid use in GI obstruction, toxic colitis, or megacolon.
Take exactly as prescribed; do not increase dose or frequency.,Do not drive or operate heavy machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report any signs of bleeding (bruising, black stools, blood in urine) or allergic reactions (rash, swelling, difficulty breathing).,Do not use in children or teenagers with chickenpox or flu symptoms due to risk of Reye's syndrome.,This medication may be habit-forming; do not stop abruptly without consulting your doctor.,Store at room temperature away from moisture and heat.
Do not add any other ingredients to the solution.,Chill the solution before drinking to improve palatability.,Drink the entire volume over the prescribed period; do not eat solid foods until after the procedure.,Expect frequent, watery bowel movements; stay near a toilet.,Take other medications at least 1 hour before starting the solution, except as directed by your doctor.,Stop drinking the solution 2-3 hours before the procedure.,If severe bloating, abdominal pain, or vomiting occurs, pause and resume later.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMA COMPOUND vs COLYTE-FLAVORED, answered by our medical review team.
SOMA COMPOUND is a Skeletal Muscle Relaxant Combination that works by Carisoprodol is a centrally acting muscle relaxant that acts through its metabolite meprobamate, which modulates GABA-A receptors and inhibits neuronal activity in the reticular formation and spinal cord. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.. COLYTE-FLAVORED is a Osmotic Laxative that works by Colyte is an osmotic laxative that induces diarrhea by retaining water in the colon through non-absorbable polyethylene glycol (PEG) and electrolytes, resulting in bowel cleansing.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMA COMPOUND and COLYTE-FLAVORED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMA COMPOUND is: 1-2 tablets (carisoprodol 200mg/aspirin 325mg) orally 4 times daily.. The standard adult dose of COLYTE-FLAVORED is: 4 liters orally as a single dose or in divided doses for colonoscopy preparation, or 1 liter orally every 10-15 minutes until 4 liters are consumed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMA COMPOUND and COLYTE-FLAVORED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMA COMPOUND is classified as Category C. Carisoprodol (Soma) is FDA Pregnancy Category C. Inadequate human data; animal studies suggest risk. Not recommended in first trimester due to potential teratogenicity. Aspirin com. COLYTE-FLAVORED is classified as Category C. Category C: Not associated with major malformations; limited data in pregnancy. No known teratogenicity; use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.